Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
CellaVision AB (publ) (CEVI.ST)
Lund, SE
CellaVision AB (publ), a Swedish enterprise established in 1994 and based in Lund, specializes in crafting and distributing advanced digital systems for analyzing blood and other bodily fluids within the healthcare industry. The company serves a global market, with operations extending across Sweden, the wider European continent, the Middle East, Africa, the Americas, and the Asia Pacific region. Their core product line includes automated digital imaging devices such as the CellaVision DM1200 and DM9600, engineered to automatically capture detailed digital images of cells from blood smears and fluid preparations. Additionally, they offer the CellaVision DC-1 analyzer. Beyond hardware, CellaVision provides a suite of specialized software applications. The CellaVision Peripheral Blood Application streamlines and standardizes the morphological assessment of peripheral blood smears, while the CellaVision Advanced RBC Application facilitates a thorough examination of red blood cell morphology. For other body fluids, the CellaVision Body Fluid Application automates and standardizes their morphological evaluation. To enhance operational flexibility, the CellaVision Remote Review Software allows for the review of digital smears without geographical restrictions. Furthermore, the company delivers tools designed for laboratory management and educational purposes. The CellaVision Server Software integrates workflows across single or multiple testing facilities into a cohesive system. The CellaVision Dashboard provides an instant, visual summary of analyzer and reviewer performance data. The cloud-based CellaVision Proficiency Software assists laboratory managers in evaluating, tracking, and developing staff competency in cell morphology. For training and reference, the CellaVision CellAtlas features concise educational modules alongside a comprehensive cell image library. CellaVision also caters to the animal health sector with CellaVision VET, offering digital microscopy solutions for veterinary hematology. These innovative solutions are primarily supplied to hospitals and commercial laboratories worldwide.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-04 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+4.9% Q1'26: -14.6% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+8.8% Q1'26: -46.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+21.5% Q1'26: +27.6% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+27.0% ★ Q1'26: +17.4% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+22.3% ★ Q1'26: +12.9% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+0.0% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.11× ★ Q1'26: 0.19× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 4 EPS Ana. |
Dec 2027 4 Rev. Ana. 4 EPS Ana. |
Dec 2028 4 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
239.39M
est: 249.86M (-4.2%)
|
265.04M
est: 259.21M (+2.2%)
|
309.31M
est: 310.50M (-0.4%)
|
364.81M
est: 349.92M (+4.3%)
|
461.77M
est: 446.49M (+3.4%)
|
471.44M
est: 481.60M (-2.1%)
|
565.55M
est: 563.40M (+0.4%)
|
639.34M
est: 673.98M (-5.1%)
|
677.29M
est: 726.40M (-6.8%)
|
723.22M
est: 738.90M (-2.1%)
|
758.97M
est: 753.67M (+0.7%)
|
823.53M
804.00M – 852.70M
+9.3% YoY
|
918.64M
875.95M – 951.35M
+11.6% YoY
|
1.02B
1.02B – 1.02B
+10.8% YoY
|
| EBITDA |
73.13M
est: 77.33M (-5.4%)
|
75.48M
est: 80.22M (-5.9%)
|
98.79M
est: 96.10M (+2.8%)
|
113.83M
est: 108.30M (+5.1%)
|
150.87M
est: 138.18M (+9.2%)
|
134.37M
est: 149.05M (-9.8%)
|
193.60M
est: 174.36M (+11.0%)
|
198.36M
est: 208.59M (-4.9%)
|
207.25M
est: 228.83M (-9.4%)
|
219.75M
est: 232.76M (-5.6%)
|
237.28M
est: 237.41M (-0.1%)
|
259.42M
253.27M – 268.61M
+9.3% YoY
|
289.39M
275.94M – 299.69M
+11.6% YoY
|
320.69M
320.68M – 320.69M
+10.8% YoY
|
| EBIT |
65.47M
est: 63.35M (+3.3%)
|
74.17M
est: 65.72M (+12.8%)
|
90.89M
est: 78.73M (+15.5%)
|
112.26M
est: 88.72M (+26.5%)
|
130.72M
est: 113.21M (+15.5%)
|
110.27M
est: 122.11M (-9.7%)
|
160.16M
est: 142.85M (+12.1%)
|
158.27M
est: 170.89M (-7.4%)
|
167.48M
est: 189.43M (-11.6%)
|
185.02M
est: 192.69M (-4.0%)
|
204.98M
est: 196.54M (+4.3%)
|
214.76M
209.67M – 222.37M
+9.3% YoY
|
239.57M
228.44M – 248.10M
+11.6% YoY
|
265.48M
265.48M – 265.49M
+10.8% YoY
|
| Net Income |
52.82M
est: 58.14M (-9.1%)
|
59.80M
est: 56.29M (+6.2%)
|
69.72M
est: 70.72M (-1.4%)
|
88.69M
est: 85.14M (+4.2%)
|
99.17M
est: 112.62M (-11.9%)
|
89.48M
est: 90.78M (-1.4%)
|
125.34M
est: 121.18M (+3.4%)
|
118.34M
est: 126.62M (-6.5%)
|
130.31M
est: 145.06M (-10.2%)
|
140.72M
est: 144.40M (-2.5%)
|
153.08M
est: 153.08M (+0.0%)
|
171.30M
160.72M – 179.77M
+11.9% YoY
|
201.08M
176.24M – 217.20M
+17.4% YoY
|
231.83M
194.94M – 264.21M
+15.3% YoY
|
| SGA |
81.64M
est: 76.66M (+6.5%)
|
85.53M
est: 79.53M (+7.5%)
|
105.54M
est: 95.27M (+10.8%)
|
120.01M
est: 107.36M (+11.8%)
|
153.74M
est: 136.99M (+12.2%)
|
151.52M
est: 147.77M (+2.5%)
|
165.32M
est: 172.86M (-4.4%)
|
191.50M
est: 206.79M (-7.4%)
|
212.66M
est: 218.34M (-2.6%)
|
221.95M
est: 222.10M (-0.1%)
|
220.23M
est: 226.53M (-2.8%)
|
247.53M
241.66M – 256.30M
+9.3% YoY
|
276.12M
263.29M – 285.95M
+11.6% YoY
|
305.99M
305.99M – 306.00M
+10.8% YoY
|
| EPS |
2.22
est: 2.44 (-8.9%)
|
2.51
est: 2.36 (+6.4%)
|
2.92
est: 2.97 (-1.5%)
|
3.72
est: 3.57 (+4.2%)
|
4.16
est: 4.72 (-11.9%)
|
3.75
est: 3.81 (-1.5%)
|
5.25
est: 5.08 (+3.3%)
|
4.96
est: 5.31 (-6.6%)
|
5.46
est: 6.08 (-10.2%)
|
5.90
est: 6.06 (-2.6%)
|
6.42
est: 6.36 (+0.9%)
|
7.17
6.74 – 7.54
+12.7% YoY
|
8.41
7.39 – 9.11
+17.3% YoY
|
9.72
8.17 – 11.08
+15.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-04-24 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P International Small Cap ETF GWX | 0.03% | 291.2K | 0.40% |
| 2 | Dimensional - International Small Cap ETF DFIS | 0.00% | 262.4K | 0.39% |
| 3 | State Street SPDR Portfolio Europe ETF SPEU | 0.00% | 7.7K | 0.07% |
| 4 | Dimensional - International Core Equity 2 ETF DFIC | 0.00% | 71.9K | 0.22% |
| 5 | State Street SPDR Portfolio Developed World ex-US ETF SPDW | 0.00% | 105.5K | 0.03% |
| 6 | Dimensional - International Core Equity Market ETF DFAI | 0.00% | — | 0.18% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Christer Fahraeus | Founder & Director | 285.0K | male |
| Elin Bredberg | Vice President of Human Resource | — | female |
| Helena Raihle | Corporate Communications & Investor Relations | — | female |
| Monica Jonsson | Interim Chief Financial Officer | — | female |
| Peter Wilson | Vice President of Business Development & Global Marketing | — | male |
| Simon Ostergaard | Chief Executive Officer & President | — | male |
| Urban Strindlov | Vice President of Global Sales | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CEVI.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
